The following is a summary of the Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript:
Financial Performance:
Net revenue for Q3 2024 was $29,000, a decrease from $42,000 in the same period a year ago.
Total operating expenses for Q3 2024 were $8.9 million, up 8% from $8.2 million in Q3 2023.
Net loss for Q3 2024 increased to $7.9 million from $7.2 million in Q3 2023.
Business Progress:
Focused on publication of clinical trial results and expanding test adoption and payer coverage.
Launched educational campaigns with significant engagement and initiated direct-to-consumer sales through new online platforms.
Continued growth in visibility and adoption through media campaigns and social media presence.
Opportunities:
Addressing increased rates of preterm births in the U.S., a significant health care challenge, via educational and awareness campaigns.
Expanding direct-to-consumer access to PreTRM tests, enhancing potential for revenue growth.
Risks:
Slow scaling of AI services may delay expected revenue growth from these innovations.
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
